Is there a reduced sensitivity of dihydroartemisinin against praziquantel-resistant Schistosoma japonicum?

Parasitology Research

Volumn 113, Issue 1, 2014, Pages 223-228

  Wang, Wei ^a,b,c   Li, Hong Jun ^d   Qu, Guo Li ^a,b,c   Xing, Yun Tian ^a,b,c   Yang, Zhen Kun ^a,b,c   Dai, Jian Rong ^a,b,c   Liang, You Sheng ^a,b,c  

^a JIANGSU INSTITUTE OF PARASITIC DISEASES   (China)

^b BEIJING HOSPITAL   (China)

^c Jiangsu Provincial Key Laboratory on Molecular Biology of Parasites   (China)

^d AFFILIATED HOSPITAL OF WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROARTEMISININ; PRAZIQUANTEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHISTOSOMA JAPONICUM; SCHISTOSOMIASIS JAPONICA;

MUS; SCHISTOSOMA JAPONICUM;

ANIMALS; ARTEMISININS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; FEMALE; MICE; MICE, INBRED ICR; PRAZIQUANTEL; SCHISTOSOMA JAPONICUM; SCHISTOSOMIASIS JAPONICA; SCHISTOSOMICIDES;

EID: 84891878051     PISSN: 09320113     EISSN: 14321955     Source Type: Journal    
DOI: 10.1007/s00436-013-3647-1     Document Type: Article

References (58)

1. Alonso D, Muñoz J, Gascón J, Valls ME, Corachan M (2006) Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Am J Trop Med Hyg 74:342-344
2. Caffrey CR (2007) Chemotherapy of schistosomiasis: present and future. Curr Opin Chem Biol 11:433-439
3. Chen MG (2005) Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years' experience. Acta Trop 96:168-176
4. Chen XY, Wang LY, Cai JM, Zhou XN, Zheng J, Guo JG, Wu XH, Engels D, Chen MG (2005) Schistosomiasis control in China: the impact of a 10-year World Bank Loan Project (1992-2001). Bull World Health Organ 83:43-48
5. Cioli D, Pica-Mattoccia L, Archer S (1993) Drug resistance in schistosomes. Parasitol Today 9:162-166
6. Cioli D, Pica-Mattoccia L (2003) Praziquantel. Parasitol Res 90:S3-S9
7. da Silva SP, Noël F (1995) Time course of the effect of praziquantel on Schistosoma mansoni attachment in vitro: comparison with its effects on worm length and motility. Parasitol Res 81:543-548
8. Doenhoff MJ, Cioli D, Utzinger J (2008) Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 21:659-667
9. Fallon PG, Doenhoff MJ (1994) Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am J Trop Med Hyg 51:83-88
10. Fallon PG, McNeice C, Probert AJ, Doenhoff MJ (1994) Quantification of praziquantel-induced damage on the surface of adult Schistosoma mansoni worms: estimation of esterase and alkaline phosphatase activity. Parasitol Res 80:623-625
11. Fallon PG, Sturrock RF, Niang AC, Doenhoff MJ (1995) Diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am J Trop Med Hyg 53:61-62
12. Fenwick A, Webster JP (2006) Schistosomiasis: challenges for control, treatment and drug resistance. Curr Opin Infect Dis 19:577-582
13. Gönnert R, Andrews P (1977) Praziquantel, a new board-spectrum antischistosomal agent. Parasitol Res 52:129-150
14. Harder A, Andrews P, Thomas H (1987) Chlorpromazine, other amphiphilic cationic drugs and praziquantel: effects on carbohydrate metabolism of Schistosoma mansoni. Parasitol Res 73:245-249
15. Harder A (2002) Chemotherapeutic approaches to schistosomes: current knowledge and outlook. Parasitol Res 88:395-397
16. Harnett W (1988) The anthelmintic action of praziquantel. Parasitol Today 4:144-146
17. Hommel M (2008) The future of artemisinins: natural, synthetic or recombinant? J Biol 7:38
18. Huang YX, Xu YL, Yu CX, Li HJ, Yin XR, Wang TS, Wang W, Liang YS (2011) Effect of praziquantel prolonged administration on granuloma formation around Schistosoma japonicum eggs in lung of sensitized mice. Parasitol Res 109:1453-1459
19. Ismail MM, Taha SA, Farghaly AM, El-Azony AS (1994) Laboratory induced resistance to praziquantel in experimental schistosomiasis. J Egypt Soc Parasitol 24:685-695
20. Ismail M, Metwally A, Farghaly A, Bruce J, Tao LF, Bennett JL (1996) Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg 55:214-218
21. Ismail M, Botros S, Metwally A, William S, Farghally A, Tao LF, Day TA, Bennett JL (1999) Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 60:932-935
22. Keiser J, Utzinger J (2012) Antimalarials in the treatment of schistosomiasis. Curr Pharm Des 18:3531-3538
23. Köhler P (2001) The biochemical basis of anthelmintic action and resistance. Int J Parasitol 31:336-345
24. Lawn SD, Lucas SB, Chiodini PL (2003) Schistosoma mansoni infection: failure of standard treatment with praziquantel in a returned traveller. Trans R Soc Trop Med Hyg 97:100-101
25. Li HJ, Liang YS, Dai JR, Wang W, Qu GL, Li YZ, Xing YT, Tao YH, Qian K, Jia Y, Yang ZK, Wei JY (2011a) Studies on resistance of Schistosoma to praziquantel XIV Experimental comparison of susceptibility to praziquantel between PZQ-resistant isolates and PZQ-susceptible isolates of Schistosoma japonicum in stages of adult worms, miracidia and cercariae. Chin J Schisto Control 23:611-619 (in Chinese)
26. Li HJ, Wang W, Liang YS (2011b) Advances in research of dihydroartemisinin against parasitic diseases. Chin J Schisto Control 23:460-464
27. Li HJ, Wang W, Li YZ, Qu GL, Xing YT, Tao YH, Wei JY, Dai JR, Liang YS (2011c) Effects of artemether, artesunate and dihydroartemisinin administered orally at multiple doses or combination in treatment of mice infected with Schistosoma japonicum. Parasitol Res 109:515-519
28. Li HJ, Wang W, Tao YH, Qu GL, Xing YT, Li YZ, Wei JY, Dai JR, Liang YS (2011d) Dihydroartemisinin-praziquantel combinations and multiple doses of dihydroartemisinin in the treatment of Schistosoma japonicum in experimentally infected mice. Ann Trop Med Parasitol 105:329-333
29. Li HJ, Wang W, Qu GL, Tao YH, Xing YT, Li YZ, Wei JY, Dai JR, Liang YS (2011e) In-vivo activity of dihydroartemisinin against Schistosoma japonicum. Ann Trop Med Parasitol 105:181-185
30. Li HJ, Wang W, Qu GL, Li YZ, Tao YH, Xing YT, Wang XT, Dai Y, Wei JY, Dai JR, Coles GC, Liang YS (2012) Effect of the in vivo activity of dihydroartemisinin against Schistosoma mansoni infection in mice. Parasitol Res 110:1727-1732
31. Li HJ, Wang W, Li YZ, Qu GL, Xing YT, Qian K, Jia Y, Yang ZK, Qian YL, Dai JR, Liang YS (2013) In vivo activity of dihydroartemisinin against Schistosoma mansoni schistosomula in mice. Southeast Asian J Trop Med Public Health 44:379-387
32. Liang YS, Li HJ, Dai JR, Wang W, Qu GL, Tao YH, Xing YT, Li YZ, Qian K, Wei JY (2011) Studies on resistance of Schistosoma to praziquantel XIII resistance of Schistosoma japonicum to praziquantel is experimentally induced in laboratory. Chin J Schisto Control 23:605-610 (in Chinese)
33. Ma Y, Lu DM, Lu XJ, Liao L, Hu XS (2004) Activity of dihydroartemisinin against Leishmania donovani both in vitro and vivo. Chin Med J (Engl) 117:1271-1273
34. Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, Wynn NB, Mutuku MW, Karanja DM, Colley DG, Black CL, Secor WE, Mkoji GM, Loker ES (2009) Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis 3:e504
35. Meshnick SR (2002) Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol 32:1655-1660
36. Ni X, Chen Y (2001) In vitro study of the anti-pneumocystis carinii effect of arteminsin derivatives. Chin J Tuberc Respir Dis 24:164-167
37. Ribeiro-dos-Santos G, Verjovski-Almeida S, Leite LC (2006) Schistosomiasis - a century searching for chemotherapeutic drugs. Parasitol Res 99:505-521
38. Prociv P (1997) A case of refractory schistosomiasis. Med J Aust 166:568
39. Sarciron ME, Saccharin C, Petavy AF, Peyron F (2000) Effects of artesunate, dihydroartemisinin, and an artesunate-dihydroartemisinin combination against Toxoplasma gondii. Am J Trop Med Hyg 62:73-6
40. Seto EY, Wong BK, Lu D, Zhong B (2011) Human schistosomiasis resistance to praziquantel in China: should we be worried? Am J Trop Med Hyg 85:74-82
41. Seubert J, Pohlke R, Loebich F (1977) Synthesis and properties of praziquantel, a novel broad spectrum anthelmintic with excellent activity against schistosomes and cestodes. Experientia 33:1036-1037
42. Silva IM, Thiengo R, Conceição MJ, Rey L, Lenzi HL, Pereira Filho E, Ribeiro PC (2005) Therapeutic failure of praziquantel in the treatment of Schistosoma haematobium infection in Brazilians returning from Africa. Mem Inst Oswald Cruz 100:445-449
43. Stelma FF, Talla I, Sow S, Kongs A, Niang M, Polman K, Deelder AM, Gryseels B (1995) Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am J Trop Med Hyg 53:167-170
44. Stelma FF, Sall S, Daff B, Sow S, Niang M, Gryseels B (1997) Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low. J Infect Dis 176:304-307
45. Tang ZH, Zhou XO, Gao XZ (2007) Effect of dihydroartemisinin on the ultrastructure of Trichomonas vaginalis trophozoites in vitro. Chin J Parasitol Parasit Dis 25:41-44
46. Tian XF, Shen HE, Li J, Chen Y, Yang ZH, Lu SQ (2010) The effects of dihydroartemisinin on Giardia lamblia morphology and cell cycle in vitro. Parasitol Res 107:369-375
47. Tchuem-Tchuenté LA, Southgate VR, Mbaye A, Engels D, Gryseels B (2001) The efficacy of praziquantel against Schistosoma mansoni infection in Ndombo, northern Senegal. Trans Roy Soc Trop Med Hyg 2001(95):65-66
48. Tu YY (2011) The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nature Med 17:1217-1220
49. Wang W, Dai JR, Li HJ, Shen XH, Liang YS (2010) Is there reduced susceptibility to praziquantel in Schistosoma japonicum? Evidence from China. Parasitology 137:1905-1912
50. Wang W, Wang L, Liang YS (2012) Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol Res 111:1871-1877
51. Webster HK, Lehnert EK (1994) Chemistry of artemisinin: an overview. Trans R Soc Trop Med Hyg 88:S27-S29
52. WHO (1993) The Control of Schistosomiasis: Second Report of WHO Expert Committee. WHO Technical Report Series No. 830. Geneva, Switzerland.
53. Wu W, Wang W, Huang YX (2011) New insight into praziquantel against various developmental stages of schistosomes. Parasitol Res 109:1501-1507
54. Wu W, Huang Y (2013) Application of praziquantel in schistosomiasis japonica control strategies in China. Parasitol Res 112:909-915
55. Xiao SH, Keiser J, Chen MG, Tanner M, Utzinger J (2010) Research and development of antischistosomal drugs in the People's Republic of China: a 60-year review. Adv Parasitol 73:231-295
56. Yu DB, Li Y, Sleigh AC, Yu XL, Li YS, Wei WY, Liang YS, McManus DP (2001) Efficacy of praziquantel against Schistosoma japonicum: field evaluation in an area with repeated chemotherapy compared with a newly identified endemic focus in Hunan, China. Trans R Soc Trop Med Hyg 95:537-541
57. Zhou YB, Zhao GM, Jiang QW (2007) Effects of the praziquantel-based control of schistosomiasis japonica in China. Ann Trop Med Parasitol 101:695-703
58. Zhou YB, Zheng HM, Jiang QW (2011) A diagnostic challenge for schistosomiasis japonica in China: consequences on praziquantel-based morbidity control. Parasit Vectors 4:194